Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Date:8/31/2013

ence of venous thromboembolism in the USA: now and future.

Thromb Haemost 2009;7 (Suppl. 2):207-8 (abstract OC-WE-018).

6.        Heit JA, Cohen AT, Anderson FAJ, on behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. ASH Annual Meeting Abstracts. 106:910. 2005.

7.        Heit JA. Venous thromboembolism epidemiology: implications for prevention and management. Seminars in Thrombosis and Hemostasis. 2002;(s2):003– 014.

8.        Ogata, K et al. Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers. J Clin Pharmacol. 2010;50:743-753.

9.        Ruff CT et al. Evaluation of the novel Factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010; Oct;160(4):635-41.

10.     Daiichi Sankyo press release - Daiichi Sankyo Launches LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, in Japan for the Prevention of Venous Thromboembolism after Major Orthopaedic Surgery. 19 July 2011. Available at: http://www.daiichisankyo.com/news/detail/004123.html. [Last accessed: July 2013].

 


'/>"/>
SOURCE Daiichi Sankyo Company, Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
2. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
5. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
6. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
7. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
8. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
9. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
10. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
11. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... The issue: Mylan Pharmaceuticals ULC Canada, in consultation with Health ... 0.4 mg/metered dose due to the product missing the "dip ... A missing "dip tube" could pose a potential problem ... may lead patients to believe they are receiving the nitroglycerin, ... receiving nitroglycerin could place them at risk for either a ...
(Date:9/19/2014)... , Sept. 19, 2014 Medical science ... relationships with key opinion leaders (KOLs) who can ... Despite the critical nature of the MSL function, ... including altering the landscape for creating and maintaining ... to research, the oversight responsibility for the MSL ...
(Date:9/19/2014)... , Sept. 19, 2014 Harwood Feffer LLP ... board of directors of PDL BioPharma, Inc. ("PDL" or ... the board has breached its fiduciary duties to shareholders ... September 16, 2014, the Company disclosed: "On September 11, ... accounting firm, Ernst & Young LLP ("EY"), that it ...
Breaking Medicine Technology:Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2Role of Medical Science Liaisons Shifting in Healthcare Industry 2Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
... 2011 ,   EP ... of the Year Award at the European Mediscience,Awards, sponsored ... award, which honours clear and concise commentary in the,pharma ... research houses or specialist websites dedicated to,providing sharp, perceptive ...
... 24, 2011 New Phase 2 clinical trial data ... of Medicine show that patients with moderate to ... bardoxolone methyl for 52 weeks experienced a sustained improvement ... by estimated glomerular filtration rate (eGFR). The data were ...
Cached Medicine Technology:EP Vantage Wins Commentator of the Year Award at European Mediscience Awards 2011 2EP Vantage Wins Commentator of the Year Award at European Mediscience Awards 2011 3New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 2New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 3New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 4
(Date:9/20/2014)... September 20, 2014 Ticket Down ... tickets . This popular ticket exchange is offering their ... , The 2015 schedule of tours is beginning to fill ... announced their plans to hit the road, including 21-year-old pop ... announced the “Honeymoon Tour,” which will take her to 25 ...
(Date:9/20/2014)... 2014 The print component of ... of the Calgary Herald, with a circulation of ... 270,000. The digital component is distributed nationally through ... network of top news sites and partner outlets. ... visit http://www.worklifebalanceinfo.ca . , The publication features ...
(Date:9/20/2014)... festival season is coming soon. The high-end fashion designer BellasDress ... dresses . A lot of sophisticated women like its new ... promotion for its high quality clothes. Now, each of its ... to 71 percent off. , The company’s cocktail dress ... in many fashionable colors. Mary, the company’s sales manager, believes ...
(Date:9/20/2014)... 2014 iFitDress.com, the popular online supplier ... has recently unveiled its new collection of cocktail gowns. ... special offer on these new outfits; it intends to ... customers can now buy cheap cocktail dresses ... representative says, “We have extensive experience in the industry ...
(Date:9/20/2014)... 20, 2014 "As a nurse, patients always ... said an inventor from Tamaqua, Pa. "The reason that they ... backs of their chairs. My invention enables them to check ... Oxygen Sensor to make it easier to monitor the contents ... knows when the tank is low. It allows changeovers to ...
Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 2Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Fashionable Cocktail Dresses Unveiled Online at iFitDress.com 2
... , , , ... leading provider of advanced clinical documentation software, workflow tools, consulting ... as Corporate Vice President of Marketing and Communications. Reporting ... with designing and implementing new marketing initiatives that blend the ...
... NEW ORLEANS, July 29 Smoothie King, the 1973 originator ... leading the way to making healthy alternatives and high-quality meal replacements available ... Consumers in Tokyo will be the first in Japan to enjoy the ... open in 2010. Japan makes sense as the latest Smoothie King market, ...
... HAIKOU CITY, China, July 29 /PRNewswire-Asia-FirstCall/ -- China ... develops,manufactures, and markets specialty pharmaceutical products in China, today,announced ... results on,Wednesday, August 12, 2009, before the market opens. ... a conference call at 8:00 am ET on August ...
... , SOUTH SAN FRANCISCO, Calif., July 29 ... biopharmaceutical company focused on innovative oncology therapies, today announced that ... to provide a corporate overview, including a discussion about the ... at two upcoming investor conferences: , , ...
... chemo, expert says , WEDNESDAY, July 29 (HealthDay News) ... tumors show promise, U.S. researchers report. , The nanoparticles ... fatty molecules that can be designed to carry a ... to control how long they remain in the bloodstream. ...
... , , DARIEN, Conn., July 29 ... Switch , a sparkling 100% juice, is expanding its availability into ... The Switch has added key retailers Tops, D,Agostinos, ... And the list of eager retailers keeps growing with Wegmans, Price ...
Cached Medicine News:Health News:Precyse Solutions Taps Former Siemens Executive to Lead New Marketing Organization 2Health News:Smoothie King Expansion Signals International Trend Toward Healthy Living 2Health News:Smoothie King Expansion Signals International Trend Toward Healthy Living 3Health News:China Pharma Holdings, Inc. to Report Second Quarter 2009 Financial Results on August 12, 2009 2Health News:Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August 2Health News:Scientists Test New Way to Get Drugs to Cancer Cells 2Health News:People Across the Country are Making The Switch! 2